These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 9158821)

  • 1. Macroprolactinaemia: contribution to hyperprolactinaemia in a district general hospital and evaluation of a screening test based on precipitation with polyethylene glycol.
    Fahie-Wilson MN; Soule SG
    Ann Clin Biochem; 1997 May; 34 ( Pt 3)():252-8. PubMed ID: 9158821
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Macroprolactinaemia: validation and application of the polyethylene glycol precipitation test and clinical characterization of the condition.
    Olukoga AO; Kane JW
    Clin Endocrinol (Oxf); 1999 Jul; 51(1):119-26. PubMed ID: 10468974
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of hyperprolactinaemia with the use of the intervals for prolactin after macroforms separation.
    Beda-Maluga K; Pisarek H; Komorowski J; Swietoslawski J; Fuss-Chmielewska J; Winczyk K
    J Physiol Pharmacol; 2014 Jun; 65(3):359-64. PubMed ID: 24930507
    [TBL] [Abstract][Full Text] [Related]  

  • 4. False-positive polyethylene glycol precipitation tests for macroprolactin due to increased serum globulins.
    Ram S; Harris B; Fernando JJ; Gama R; Fahie-Wilson M
    Ann Clin Biochem; 2008 May; 45(Pt 3):256-9. PubMed ID: 18482912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reference ranges for serum total and monomeric prolactin for the current generation Abbott Architect assay.
    Whitehead SJ; Cornes MP; Ford C; Gama R
    Ann Clin Biochem; 2015 Jan; 52(Pt 1):61-6. PubMed ID: 25074991
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Macroprolactin screening in 464 patients with hyperprolactinaemia.
    Lim MH; Ho CKM
    Malays J Pathol; 2022 Aug; 44(2):261-267. PubMed ID: 36043589
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and radiological features of patients with macroprolactinaemia.
    Strachan MW; Teoh WL; Don-Wauchope AC; Seth J; Stoddart M; Beckett GJ
    Clin Endocrinol (Oxf); 2003 Sep; 59(3):339-46. PubMed ID: 12919157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A possible cause of the variable detectability of macroprolactin by different immunoassay systems.
    Hattori N; Aisaka K; Shimatsu A
    Clin Chem Lab Med; 2016 Apr; 54(4):603-8. PubMed ID: 26457779
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cross-reactivity in assays for prolactin and optimum screening policy for macroprolactinaemia.
    Smith TP; Kelly S; Fahie-Wilson MN
    Clin Chem Lab Med; 2022 Aug; 60(9):1365-1372. PubMed ID: 35708266
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Macroprolactinaemia: prevalence and aetiologies in a large group of hospital workers.
    Hattori N; Ishihara T; Saiki Y
    Clin Endocrinol (Oxf); 2009 Nov; 71(5):702-8. PubMed ID: 19486017
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determination of prolactin: the macroprolactin problem.
    Fahie-Wilson M; Smith TP
    Best Pract Res Clin Endocrinol Metab; 2013 Oct; 27(5):725-42. PubMed ID: 24094642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Importance of screening for macroprolactin in all hyperprolactinaemic sera.
    Jamaluddin FA; Sthaneshwar P; Hussein Z; Othman N; Chan SP
    Malays J Pathol; 2013 Jun; 35(1):59-63. PubMed ID: 23817395
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The detection of macroprolactin by precipitation and ultrafiltration methods.
    Beda-Maluga K; Pisarek H; Komorowski J; Pawlikowski M; Świętosławski J; Winczyk K
    Endokrynol Pol; 2011; 62(6):529-36. PubMed ID: 22144220
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interference by macroprolactin in assays for prolactin: will the
    Fahie-Wilson MN; Cobbaert CM; Horvath AR; Smith TP
    Clin Chem Lab Med; 2022 Aug; 60(9):1350-1355. PubMed ID: 35704648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyperprolactinaemia does not always mean 'hyperprolactinaemia'!
    Gezer A; Atasü T; Hekim C; Stenman UH; Hekim N
    Eur J Obstet Gynecol Reprod Biol; 2005 Feb; 118(2):206-8. PubMed ID: 15653204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Screening for macroprolactinaemia and pituitary imaging studies.
    Hauache OM; Rocha AJ; Maia AC; Maciel RM; Vieira JG
    Clin Endocrinol (Oxf); 2002 Sep; 57(3):327-31. PubMed ID: 12201824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Coexistence of macroprolactinaemia and hyperprolactinaemia in women with oligo-/amenorrhoea is associated with high risk of pituitary adenomas.
    Lewandowski KC; Gasior-Perczak D; Kowalska A; Lewinski A
    Gynecol Endocrinol; 2014 May; 30(5):385-7. PubMed ID: 24533748
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Roche Elecsys Prolactin II assay: reactivity with macroprolactin compared with eight commercial assays for prolactin and determination of monomeric prolactin by precipitation with polyethylene glycol.
    Fahie-Wilson M; Bieglmayer C; Kratzsch J; Nusbaumer C; Roth HJ; Zaninotto M; Plebani M; Hubbuch A; Schneider E
    Clin Lab; 2007; 53(5-6):301-7. PubMed ID: 17605405
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum prolactin revisited: parametric reference intervals and cross platform evaluation of polyethylene glycol precipitation-based methods for discrimination between hyperprolactinemia and macroprolactinemia.
    Overgaard M; Pedersen SM
    Clin Chem Lab Med; 2017 Oct; 55(11):1744-1753. PubMed ID: 28236625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gross variability in the detection of prolactin in sera containing big big prolactin (macroprolactin) by commercial immunoassays.
    Smith TP; Suliman AM; Fahie-Wilson MN; McKenna TJ
    J Clin Endocrinol Metab; 2002 Dec; 87(12):5410-5. PubMed ID: 12466327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.